Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 May 2015

De Mattia Elena, Cecchin Erika, Toffoli Giuseppe

Abstract excerpt

Colorectal cancer (CRC) represents one of the most common malignancies and is major cause of cancer-related deaths worldwide. A great improvement in response rate and patient's survival was recently achieved through the introduction of new targeted agents including the anti-EGFR monoclonal antibodies cetuximab and panitumumab, the anti-angiogenic drugs bevacizumab and aflibercept, as well as the multi-kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Inactivation, Metabolic

Share to Mutation

Share to Precision Medicine

Share to Signal Transduction

Source

Identifiers

PMID: 26027741
DOI: 10.1016/j.drup.2015.05.003

Genes

EGFR
PTEN
BRAF
EGF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.PMID 26027741Read ↗

Pharmacogenomics in colorectal cancer: The first step for individualized-therapySemantic proximity Read ↗

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSemantic proximity Read ↗

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer TreatmentSemantic proximity Read ↗

Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study.Semantic proximity Read ↗

Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.Semantic proximity Read ↗

Genetic polymorphisms and tumoral mutational profile over survival in advanced colorectal cancer patients: an exploratory studySemantic proximity Read ↗

Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.Semantic proximity Read ↗

Cellular mechanisms of acquired drug resistance against regorafenib in colon cancer cellsSemantic proximity Read ↗

Somatic pharmacogenomics in the treatment prognosis of locally advanced rectal cancer patients: a narrative review of the literature.Semantic proximity Read ↗

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Semantic proximity Read ↗

FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.Semantic proximity Read ↗

[Recent developments of pharmacogenomics in the treatment of colorectal cancers].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.